Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

  • Investigating potential for an oral treatment in diabetic retinopathy
  • First patient dosed in Phase 1b/2a clinical trial

Copenhagen, Denmark, 25 January 2024  Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular edema (DME).

Breye is developing novel, oral ophthalmology drugs to address the need for more effective and less burdensome therapies for millions of patients suffering with deteriorating vision due to Diabetic Retinopathy (DR) or Age-Related Macular Degeneration (AMD). While there has been successful development of intravitreally administered products for patients with late-stage disease, treatment options are currently limited for patients in the early or moderate stages.

Read more…